This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Adult respiratory distress syndrome

Authoring team

Adult respiratory distress syndrome/acute respiratory distress syndrome (ARDS) is characterised by fulminant interstitial and alveolar oedema which usually develops 12 to 48 hours after an initial insult, resulting from increased alveolar-capillary permeability rather than a cardiogenic cause (1, 5):

  • injury may occur directly (e.g. pneumonia, gastric aspiration, smoke inhalation) or indirectly as part of a generalised systemic acute inflammatory process (e.g. nonpulmonary sepsis, severe trauma, pancreatitis, blood-product transfusion) (1, 5)
  • occurs in approximately 10% of all patients in intensive care units (ICUs) worldwide (1), with in-hospital mortality remaining high at 30-46% depending on severity (5)
  • while most survivors recover normal or near-normal pulmonary function, around a third have residual pulmonary disability due to pulmonary fibrosis, and functional disability, exercise limitation, and psychological sequelae can persist for up to 5 years (5)

Definitions of ARDS in adults

2012 Berlin definition (2)

  • timing: respiratory failure within 1 week of a known insult or new and/or worsening respiratory symptoms
  • origin: respiratory failure not fully explained by cardiac function or volume overload (echocardiography suggested to exclude hydrostatic oedema if no risk factor is present)
  • imaging: bilateral opacities on chest radiograph or CT not fully explained by effusion, collapse or nodules
  • oxygenation: acute onset of hypoxaemia defined as PaO2/FiO2 <= 300 mmHg on at least PEEP or CPAP 5 cmH2O (2)
    • PaO2/FiO2 of 201-300 mmHg is mild ARDS
    • PaO2/FiO2 of 101-200 mmHg is moderate ARDS
    • PaO2/FiO2 <= 100 mmHg is severe ARDS

2016 Kigali modification (3)

  • timing and origin: as in the Berlin definition
  • imaging: bilateral opacities on chest radiography or ultrasonography scan not fully explained by effusion, collapse or nodules
  • oxygenation: SpO2/FiO2 < 315; no PEEP requirement

Global Definition of ARDS (2024) (5)

  • expands criteria to include patients managed with high-flow nasal oxygen (HFNO) and patients in resource-limited settings without access to arterial blood gas testing, radiography, or positive-pressure ventilation:
    • timing and origin: within 1 week of an acute insult; oedema not fully explained by cardiac failure or fluid overload
    • imaging: bilateral opacities on chest radiograph or CT, or bilateral B-lines or opacities on lung ultrasonography (not fully explained by atelectasis, effusion, or nodules)
    • oxygenation: PaO2/FiO2 <= 300 mmHg or SpO2/FiO2 <= 315 (when SpO2 <= 97%)
    • categories:
      • intubated patients: mild (PaO2/FiO2 201-300 mmHg or SpO2/FiO2 236-315), moderate (PaO2/FiO2 101-200 mmHg or SpO2/FiO2 149-235), or severe (PaO2/FiO2 <= 100 mmHg or SpO2/FiO2 <= 148) on PEEP >= 5 cmH2O
      • nonintubated patients: receiving HFNO at >= 30 L/min or noninvasive support with CPAP >= 5 cmH2O
      • resource-limited settings: SpO2/FiO2 <= 315 without requirement for supplemental oxygen or positive-pressure ventilation

ARDS, acute respiratory distress syndrome; CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen; HFNO, high-flow nasal oxygen; PaO2, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure; SpO2, peripheral capillary oxygen saturation.

Pathogenesis and pathological stages

  • ARDS results from alveolar-capillary barrier injury, dysregulated innate and adaptive immunity, microvascular thrombosis, and impaired lung repair:
    • pro-inflammatory cytokines (tumour necrosis factor, IL-1, IL-6, IL-8, IL-18) recruit neutrophils and activate macrophages, releasing reactive oxygen species, proteases, and neutrophil extracellular traps (NETs) that damage capillary endothelium and alveolar epithelium
    • protein-rich alveolar oedema, surfactant loss, and alveolar collapse lead to impaired gas exchange, ventilation-perfusion mismatch, and reduced lung compliance ("stiff lungs")
  • pathological stages (4):
    • exudative stage: initial stage characterised by diffuse alveolar damage and hyaline membrane formation
    • proliferative stage: develops after approximately 10-14 days, with oedema resolution, type II alveolar cell proliferation, myofibroblast infiltration, and early collagen deposition
    • fibrotic stage: develops in some patients, characterised by obliteration of normal lung architecture, diffuse fibrosis, and cyst formation

Summary of management and subphenotypes (5)

  • management centres on treating the underlying trigger (e.g. antimicrobials and source control in sepsis/pneumonia) while preventing ventilator-induced lung injury (VILI) and fluid overload:
    • core evidence-based interventions: low-tidal-volume mechanical ventilation (6 mL/kg predicted body weight; plateau pressure <= 30 cmH2O), conservative fluid balance once shock has resolved, and early prolonged prone positioning (>= 16 hours/day) in moderate-to-severe ARDS (PaO2/FiO2 < 150 mmHg)
    • selective/rescue options: higher PEEP, short-course neuromuscular blockade for severe dyssynchrony or worsening hypoxaemia, early glucocorticoids (established in COVID-19 ARDS; under ongoing evaluation in non-COVID-19 ARDS), and venovenous ECMO for refractory hypoxaemia or severe acidosis
    • emerging subphenotypes: distinct biologic (hyperinflammatory vs hypoinflammatory), physiological (low vs high compliance), and radiologic (diffuse vs focal) subphenotypes show differential mortality and treatment responses, guiding ongoing precision-medicine trials

Reference:

  1. Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. Published 2019 Mar 14. doi:10.1038/s41572-019-0069-0.
  2. Ranieri VM, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526-2533.
  3. Riviello ED, et al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali Modification of the Berlin Definition. Am. J. Respir. Crit. Care Med. 2016;193:52-59. doi: 10.1164/rccm.201503-0584OC
  4. Rawal G, Yadav S, Kumar R. Acute Respiratory Distress Syndrome: An Update and Review. J Transl Int Med. 2018;6(2):74-77. Published 2018 Jun 26. doi:10.1515/jtim-2016-0012
  5. Calfee CS, McAuley DF. Acute Respiratory Distress Syndrome. N Engl J Med. 2026;395(20):2027-2042. doi:10.1056/NEJMra2601172.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page